Lakeshore Biopharma Co. Ltd.Preferred / convertible
13F holders, Q3 2025 (September 30)3holders −16
0new positions
14sold out
$0.00avg. 13F price*
At the end of Q3 2025, 3 institutions reported holding Lakeshore Biopharma Co. Ltd. in their 13F filings, down 16 from Q2 2025. 0 opened new positions and 14 sold out. The largest holders were HGC Investment Management Inc. ($25), Ancora Advisors LLC ($7) and SkyView Investment Advisors, LLC ($0).
- Company
- Lakeshore Biopharma Co. Ltd.
- Filed as
- SUMMIT HEALTHCARE ACQUISITION (Q3 2025)
- CUSIP
- G9845F117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 14 | $298K |
All 13F filers, Q2 2025 → Q3 2025: 4,326,321 shares sold, net −4,326,321 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| HGC Investment Management Inc. | — | No change | 5,000 | $25 |
| Ancora Advisors LLC | — | No change | 5,050 | $7 |
| SkyView Investment Advisors, LLC | — | No change | 12,210 | $0 |
"% of holder's portfolio" is LAKESHORE BIOPHARMA CO LTD's weight in each manager's 13F, not the share of Lakeshore Biopharma Co. Ltd. the manager owns.